Drug Pipeline
2 drugs associated with Sporadic fatal insomnia
| Drug | Phase | Sponsor | |
|---|---|---|---|
PRNP-targeting ASOs | Phase 1 | ||
Quinacrine The exact mechanism of antiparasitic action is unknown; however, quinacrine binds to deoxyribonucleic acid (DNA) in vitro by intercalation between adjacent base pairs, inhibiting transcription and translation to ribonucleic acid (RNA). Quinacrine does not appear to localize to the nucleus of Giaridia trophozoites, suggesting that DNA binding may not be the primary mechanism of its antimicrobial action. Fluorescence studies using Giardia suggest that the outer membranes may be involved. Quinacrin | Phase 2 | University of California, San Francisco | ↗ |